Prospects for rheumatoid arthritis pharmacotherapy: New opportunities and recommendations

Nasonov, E.

doi:10.17116/terarkh201688124-10

Cited by 4 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The primary method of achieving and increasing the duration of the RA remission stages is long-term use of the disease-modifying anti-rheumatic drugs (DMARD) and genetically engineered biologic drugs (GEBD), which reduce the activity of the inflammatory and autoimmune process. A large number of publications of domestic and foreign authors devoted to various approaches to the RA treatment confirm that the application of this approach in the RA treatment has resulted in tremendous progress [11], [12], [13], [14], [15], [16], [17], [18], [19], [20].…”

Section: Introductionmentioning

confidence: 99%

Comparative Analysis of Approaches and Treatment Results of Patients with Early and Nonearly Rheumatoid Arthritis

Pashanova¹,

Lopatina²,

Krivosheev³

et al. 2019

Open Access Maced J Med Sci

View full text Add to dashboard Cite

The article presents the results of a comparative analysis of different therapy regimens impact on the effectiveness of treatment of patients with early and late rheumatoid arthritis in steady-state. Data on ongoing basis anti-inflammatory therapy of rheumatoid arthritis and the treatment of associated conditions were obtained by continuous copying from case histories of hospital department patients. The observations lasted 12 months. The activity of rheumatoid arthritis before and after the treatment was determined by the DAS 28 (Disease Activity Score) index. The treatment results were evaluated as per the laboratory research and the DAS 28 index, including the counting of painful and swollen joints, erythrocyte sedimentation rate, and health assessment of the patient on a visual analogue scale.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparative Analysis of Approaches and Treatment Results of Patients with Early and Nonearly Rheumatoid Arthritis

Pashanova¹,

Lopatina²,

Krivosheev³

et al. 2019

Open Access Maced J Med Sci

View full text Add to dashboard Cite

show abstract

“…Treatment mainly involves alternative and symptomatic treatment, which aim to relieve the clinical symptoms of patients and reduce joint injury (5), and includes psychotherapy, drug therapy, and surgical treatment. Drug therapy can reduce Original Article Systematic review and meta-analysis on the efficacy of methotrexate in rheumatoid arthritis joint pain and inflammation (6); commonly used drugs include non-steroidal anti-inflammatory drugs (NSAIDs) and disease modifying anti-rheumatic drugs (DMARDs), glucocorticoids (GCs), and biologic agents (7). Of the four types of drugs, NSAIDs primarily inhibit the production of prostaglandins to achieve anti-inflammatory and analgesic effects, thereby reducing joint pain (8).…”

Section: Introductionmentioning

confidence: 99%

Systematic review and meta-analysis on the efficacy of methotrexate in rheumatoid arthritis

Jiang

Jin

Chen³

et al. 2021

Ann Palliat Med

View full text Add to dashboard Cite

Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease dominated by chronic inflammation of the synovium of the joints. Methotrexate (MTX) is the most widely used in the treatment of RA. This study systematically evaluated the clinical efficacy of MTX on RA and provided a theoretical basis for the clinical treatment of RA.Methods: Four English databases (PubMed, Embase, Medline, and Web of Sciences) were searched for randomized controlled trials (RCTs) on MTX treatment of RA published from the date of establishment of the database to 2021. The Cochrane Handbook 5.0.2 was used to perform risk bias evaluation and Review Manager 5.3 was used to conduct a meta-analysis.Results: A total of eight articles were included. The meta-analysis showed that, compared to the control group, the number of patients with DAS28-ESR ≤2.6 [erythrocyte sedimentation rate (ESR)] in the MTX alone or MTX combined treatment groups was higher, and the incidence of adverse events was also higher.However, there was no significant difference in the level of alanine aminotransferase (ALT) after treatment versus the control group.Discussion: MTX alone or MTX combined treatment can better control the condition of RA patients without causing damage to the patient's blood system or liver and kidney function, but may increase the probability of adverse events.

show abstract

“…The addition of the anti-TNF and later other biologic DMARDs, targeting specific cytokines (e.g., IL-6 and IL-1), of anti-B cell therapies (e.g., rituximab) and therapies targeting other important pathways of inflammation (e.g., abatacept) in our therapeutic armamentarium has been a true revolution which has enabled a significant proportion of our RA patients to achieve remission or at least a low disease activity state -particularly when used in a "treat-to-target" (T2T) fashion. These developments are now being followed with the introduction of small-molecule anti-inflammatory compounds such as inhibitors of Jak-family kinases, Syk tyrosine kinase, and p38 MAP kinase 12,13 that target intracellular signal transduction pathways. In contrast to biologics, the small molecules are orally administered; they have a short in vivo half-life and are stable during storage.…”

mentioning

confidence: 99%

“…At present, eight drugs related to biological therapy of RA are registered and used for patient treatment in Russia. 12 The Russian Association of Rheumatologists has priority research programs such as RADICAL, REMARKA, and ETALON for studies of methotrexate and biological agents for RA treatment. 14 For example, the RADICAL program is aimed to assess the disease activity, functional status, and X-ray changes in patients with early RA treated by traditional DMARDs and biological agents.…”

mentioning

confidence: 99%

Current and future trends in Russian Rheumatology Care and Research

Tchetina¹

2017

MJR

View full text Add to dashboard Cite

This short article provides a description of the present state of rheumatology care and research in Russia and discusses opportunities for development and cooperation. Rheumatic diseases (RDs) in Russia represent the second most common pathology after cardiovascular disorders. Although RDs include more than 200 diseases and syndromes, the most common in Russia are osteoarthritis (OA), rheumatoid arthritis (RA), gout, and low back pain, largely similar to those seen in most Western societies. Interestingly, the prevalence of RA appears to have increased from 0.42% to 1% in the Russian population since the last large-scale epidemiologic study, which was conducted 25 years ago in the former USSR; this is an opposite trend to that seen in most Western countries 1 and is similar to other reports that have indicated that RA prevalence has risen in Europe and North America due to the underlying aging population 2 and increasing patient survival. 3 This would be interesting to study in comparative collaborative research. Approximately 10% of the Russian population is presently affected by RDs. 4 The major factors responsible for the increased prevalence of RDs in Russia include increased mutation activity associated with environmental pollution and an augmented incidence of concomitant disorders such as obesity, diabetes mellitus, hypertension, and others. Recent large epidemiologic study including 76,000 subjects from 18 regions of the Russian Federation revealed that statistical indices are significantly lower (up to 5-fold) than real prevalence of RDs among adults registered according to the attendance in clinics. 5 Besides, individual federal regions demonstrate different dynamics. For example, in Central Russia, the incidence of almost all RDs excluding osteoporosis decreased, while in the Western region, an increase in the incidence of RA and OA during one year of follow-up was observed. 6 Russia is a large territory and has a multinational population. This provides the opportunity to study different disease subtypes and phenotypes associated with genetic variability, national psychological traits, various climates, ecological conditions, and environmental factors. However, all these possibilities are limited by the insufficient funding of rheumatic research. Therefore, such type of research is a subject for future studies. Recently, Russia is developing a three-level standardized system for management of RD patients involving primary medical care, specialized treatment protocols, and rehabilitation technologies developed by the leading rheumatologic centers. Russia has great tradition in rehabilitation. Recent studies on combination of "treat to target" therapies with concomitant rehabilitation program have demonstrated that this approach is more efficient than pharmacological therapy alone primarily for early RA patients. It involves

show abstract

Prospects for rheumatoid arthritis pharmacotherapy: New opportunities and recommendations

Cited by 4 publications

References 31 publications

Comparative Analysis of Approaches and Treatment Results of Patients with Early and Nonearly Rheumatoid Arthritis

Comparative Analysis of Approaches and Treatment Results of Patients with Early and Nonearly Rheumatoid Arthritis

Systematic review and meta-analysis on the efficacy of methotrexate in rheumatoid arthritis

Current and future trends in Russian Rheumatology Care and Research

Contact Info

Product

Resources

About